Direct-to-consumer model disrupts traditional pharmaceutical distribution
Hims & Hers argued that the traditional pharmacy benefit manager (PBM) and insurance model is being bypassed by direct-to-consumer platforms that dramatically drive down drug prices.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day — no card required.